Rhoen Klinikum (ETR:RHK) received a €22.00 ($26.19) price target from investment analysts at Deutsche Bank in a research report issued to clients and investors on Monday. The firm currently has a “neutral” rating on the stock. Deutsche Bank’s price target would indicate a potential downside of 29.08% from the stock’s previous close.
Several other analysts also recently issued reports on RHK. Baader Bank set a €24.00 ($28.57) price target on Rhoen Klinikum and gave the stock a “neutral” rating in a report on Friday, November 10th. Commerzbank set a €25.00 ($29.76) target price on Rhoen Klinikum and gave the company a “neutral” rating in a research note on Friday, November 10th. Warburg Research set a €26.30 ($31.31) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research note on Tuesday, November 7th. Berenberg Bank set a €29.15 ($34.70) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research note on Monday, November 6th. Finally, Independent Research set a €32.00 ($38.10) price objective on Rhoen Klinikum and gave the stock a “neutral” rating in a research note on Monday, November 13th. Four investment analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of €25.05 ($29.82).
Shares of Rhoen Klinikum (ETR:RHK) opened at €31.02 ($36.93) on Monday. The firm has a market capitalization of $2,080.00 and a P/E ratio of 1,551.00. Rhoen Klinikum has a 12 month low of €22.66 ($26.98) and a 12 month high of €31.24 ($37.19).
RH??N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services in the areas of cardiological and coronary diseases, neurological disorders, oncology, lung diseases, and orthopedic and accident surgeries; rehabilitation services; and thoracic, pulmonary and vascular diseases, tumors, heart conditions, and nervous and skeletal system diseases.
Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.